Overcoming Adversity & Building Resilience - The speaker's story highlights the power of resilience and a "never give up" attitude in overcoming societal expectations and personal challenges [2][3][7] - Early experiences of being underestimated and rejected fueled the speaker's determination to succeed [1][9] - Seeking help and support from others is a crucial tool for overcoming obstacles [12] Entrepreneurial Journey & Business Strategy - The speaker started an entrepreneurial journey in 2013, facing rejection and underestimation but driven by a grit to win [9] - The company initially focused on underserved areas within intellectual property, specifically startups, universities, and memes [14] - The company chose to build a legacy business rather than a short-term venture [14] - The company grew from zero to over 300 team members [14] Lessons Learned & Future Vision - Rejection should be seen as redirection, and individuals should focus on self-improvement rather than external judgment [17] - Resilience is more important than resources; building a network is crucial for success [17][18] - Individuals should compete with themselves, focusing on personal growth and future potential [18] - Fearlessness and boldness are key to creating a legacy [19]

Core Insights - Kadimastem has secured a patent in Hong Kong for its IsletRx technology, enhancing its global intellectual property (IP) portfolio, which already includes patents in Europe, the United States, and India [1][2][3] - The IsletRx platform aims to provide a scalable source of insulin-producing islet-like cells to address diabetes, a significant health challenge affecting millions globally [5][3] - The economic impact of diabetes in Hong Kong is substantial, with an estimated 706,000 adults affected, leading to lifetime healthcare costs averaging $125,000 per patient, translating to a potential economic burden of approximately $90 billion [3][4] Company Overview - Kadimastem Ltd. is a clinical-stage cell therapy company focused on developing allogeneic, "off-the-shelf" cell products for neurodegenerative diseases and diabetes [7] - NLS Pharmaceutics Ltd. is a Swiss-based biopharmaceutical company dedicated to innovative therapies for central nervous system disorders [6]

Core Viewpoint - Dragonfly Energy Holdings Corp. has secured a new U.S. patent for its Wakespeed® Charge Control technology, enhancing its competitive position in the energy storage industry and expanding its intellectual property portfolio [1][8]. Group 1: Patent and Technology - The newly issued patent (No. 12,403,782) focuses on the transfer of power from a towing vehicle to a trailer for charging onboard batteries, which is a significant advancement in vehicle-to-trailer charging capabilities [1][2]. - The Wakespeed Charge Control technology allows for power transfer at kilowatt levels and higher voltages (such as 48V and beyond), addressing the limitations of traditional 12V connectors [2][3]. - The technology includes safety features to prevent electrical arcs and ensure reliable operation during various connection scenarios [2][3]. Group 2: Competitive Position and Strategy - The patent reinforces Dragonfly Energy's competitive position by protecting technology that integrates batteries, alternators, and charging systems safely and efficiently [3][8]. - With approximately 100 patents filed, pending, or granted, the company is expanding its intellectual property portfolio, which supports OEM adoption and creates opportunities for technology integration across various platforms [4][8]. - The company is strategically shifting from a focus solely on batteries to providing full power system solutions across multiple industries [3][8]. Group 3: Company Overview - Dragonfly Energy specializes in lithium battery technology, including cell manufacturing, battery pack assembly, and full system integration, with its Battle Born Batteries® brand being a leader in the industry [5]. - The company employs a patented dry electrode manufacturing process that enables chemistry-agnostic power solutions for diverse applications, including energy storage systems and electric vehicles [5].

Core Insights - STRATA Skin Sciences, Inc. is focused on expanding its market by pursuing the inclusion of expanded CPT codes for its XTRAC excimer laser treatments, targeting all inflammatory and autoimmune skin conditions, with implementation expected by January 1, 2026 [1][5] - The company emphasizes its strong patent portfolio, which provides intellectual property and market exclusivity for combination therapies, enhancing its competitive position against inferior technologies [2][3] - STRATA's patents are critical for establishing rights around combination therapies that are likely to become standard care for difficult-to-treat dermatologic conditions, positioning the company at the forefront of integrative dermatologic treatment [3][4] Patent and Technology Developments - STRATA holds three key patents related to the use of Excimer laser therapy in combination with systemic drugs, which are essential for addressing limitations in treating severe or systemic skin diseases [3][4] - The patents enable a synergistic therapeutic effect, potentially leading to enhanced treatment responses, prolonged remission, and improved safety by limiting UV exposure to affected areas [4] Market Expansion and Financial Implications - The American Medical Association's approval of updates to CPT codes will expand reimbursement eligibility for XTRAC treatments, effectively tripling the addressable patient population and improving treatment economics for providers and the company [5] - STRATA's partnership program offers a fee per treatment cost structure, which may enhance revenue opportunities and market penetration [7]

At the moment, we're seeing Chinese rivals gain on the back of this lack of in video competition right now. What do you make of it. Well, all I know is we're going to have to figure out there's a long race here and a short race here.And we have to secure not only our global leadership, but also our intellectual property. And that's really some of the underpinning of the discussions here of is there a 15%, is there not a 15%. What does this mean from an export control.So a lot more to come on this, but obvio ...

Core Viewpoint - Alpha Modus Holdings Inc. has filed a patent infringement lawsuit against Cooler Screens, alleging infringement of its patented technologies related to in-store consumer engagement and analytics [1][3] Group 1: Legal Actions - The lawsuit was filed in the United States District Court for the Northern District of Illinois (Case No. 1:25-cv-10004) [1] - This action follows recent settlements of separate lawsuits against Kroger and Walgreens regarding their Cooler Screens technology deployments, with terms of those settlements being confidential [2] Group 2: Company Commitment - The CEO of Alpha Modus emphasized the company's commitment to developing and protecting innovations that enhance the in-store experience [3] - The complaint asserts that Cooler Screens' digital smart display systems infringe on methods and systems claimed in Alpha Modus patents [3] Group 3: Company Overview - Alpha Modus Holdings Inc. is focused on redefining the retail experience through patented AI technologies, intelligent kiosks, and targeted consumer engagement tools [4] - The company aims to unlock new monetization pathways for retailers and fintech providers by integrating innovation with infrastructure [4]

Intellectual Property (IP) Management - Story Protocol 旨在成为知识产权的 Layer 1 解决方案 [1] - 平台提供在几秒钟内注册 IP 的能力 [1] - 建立去中心化的 IP 市场 [1] - 具备自动版税和收入追踪功能 [1] Trading & Market Access - Story Protocol 的 $IP 可以在 MEXC 上进行交易，且交易手续费为零 [1]

Core Viewpoint - Pop Mart has experienced a significant surge in net profit and revenue, driven by the popularity of its Labubu dolls, but faces potential long-term risks due to changing consumer preferences and regulatory scrutiny on blind-box toys [1][3][4]. Financial Performance - Pop Mart's revenue increased by 204.4% year on year to 13.88 billion yuan ($1.93 billion) for the first half of 2025 [1]. - The net profit attributable to shareholders soared by 396.5% to 4.57 billion yuan [1]. - The company's stock has rallied over 200% since the beginning of the year [4]. Market Dynamics - The Labubu plushies have gained global popularity, with notable appearances on the bags of celebrities like Rihanna and Blackpink's Lisa [2]. - The Asia-Pacific region, excluding China, is the largest overseas market for Pop Mart, with revenue soaring by 257.8% to 2.85 billion yuan [4]. - The Americas represent the second-largest overseas market, with revenue jumping over 1,000% to 2.26 billion yuan [4]. Regulatory Environment - Chinese state media has called for stricter oversight of blind-box toys, suggesting measures such as age verification and parental consent for online purchases [3]. - While not directly naming Pop Mart, state media criticized businesses for encouraging excessive spending on mystery boxes [3]. Business Strategy - Intellectual Property is central to Pop Mart's business model, and the company aims to continue expanding its global footprint [5].

I used to just want to be funny in school. Yeah. >> But I got in trouble for it.So I was kind of confused early on because I didn't really know, >> am I supposed to be doing this. You know what I mean. Because everybody painted to be like a bad thing in school.So um yeah, it is it is amazing how uh it actually transpired throughout life. I had to figure out what my purpose was. I just wanted to build out my IP and like >> I looked up to, you know, the Adam Sandler um story of how he built up Happy Madison a ...

Core Insights - The United States Patent and Trademark Office (USPTO) has issued Patent No. US 12,343,315 B2 to Avicanna Inc. for its topical cannabinoid compositions aimed at promoting clear skin [1][2] - The patent covers a topical gel formulation that combines cannabinoids with antioxidants, anti-microbial agents, and anti-inflammatory agents, targeting skin diseases such as acne, wrinkles, rosacea, and erythema [2] - Avicanna's CEO expressed enthusiasm about the patent, highlighting its potential in the company's commercial platforms and pharmaceutical pipeline [3] Company Overview - Avicanna is a biopharmaceutical company focused on developing, manufacturing, and commercializing plant-derived cannabinoid-based products for the medical and pharmaceutical markets [4] - The company has a robust scientific platform that includes R&D and clinical development, leading to over thirty proprietary, evidence-based finished products [4] - Avicanna operates multiple business pillars, including a medical cannabis formulary (RHO Phyto™), a medical cannabis care platform (MyMedi.ca), a pharmaceutical pipeline, and a subsidiary (Santa Marta Golden Hemp SAS) that supplies active pharmaceutical ingredients [4][7]